Experimental Weight Loss Drug Delivers Historic 30% Body Weight Reduction

Revolutionary Results Rival Surgery

Eli Lilly's experimental obesity drug retatrutide has delivered unprecedented results in clinical trials, with participants losing an average of up to 30.3% of their body weight—outcomes that rival bariatric surgery without going under the knife. At the highest dose of 12 milligrams, participants achieved an average weight loss of 28.3%, or 70.3 pounds, compared to just 2.2% for those in the placebo group.

The 80-week Phase 3 trial evaluated the efficacy and safety of retatrutide in 2,339 adults without diabetes, making it one of the largest studies of its kind. A significant milestone was reached when a high proportion of participants dropped their body mass index below 30, effectively moving them out of the obesity category.

Dan Skovronsky, Lilly's chief scientific and product officer, called the 30% weight loss an "incredible number to see," as it has previously only been associated with bariatric surgery. Industry analysts estimate the global GLP-1 market topped $50 billion in 2024 and could exceed $150 billion by the end of the decade.

Triple-Action Mechanism Sets New Standard

Unlike existing obesity injections, retatrutide is a first-in-class molecule that targets three different metabolic hormones: GIP, GLP-1, and glucagon. Like Lilly's diabetes and obesity drugs Mounjaro and Zepbound, retatrutide is an agonist of GLP-1 and GIP, but also adds a third hormone, glucagon, to serve people who need effects beyond those driven by Lilly's existing injectable obesity blockbusters.

The drug demonstrated dose-dependent effectiveness across multiple strengths, with the 9-milligram dose yielding a 25.9% reduction and the 4-milligram dose achieving a 19% reduction. Beyond weight loss, the treatment led to broad improvements across key cardiometabolic risk markers, including waist circumference, blood pressure, and cholesterol levels.

Side Effects Prompt Some Discontinuations

Gastrointestinal events, such as nausea, diarrhea, vomiting, and constipation, were the most frequently reported adverse effects compared to the placebo. Patients experienced higher rates of nausea and diarrhea compared to existing drugs, with some patients dropping out because they lost too much weight.

The blowout efficacy was offset by a higher discontinuation rate than in an earlier retatrutide study. A lower dose of retatrutide that Lilly tested in the latest study was also associated with fewer discontinuations due to side effects. Some analysts previously said those side effects highlight the speed and strength of the drug's weight loss.

Path to Market Accelerates

The results bring Lilly one step closer to filing for approval of the weekly injection, which works differently from existing shots and pills from both Lilly and Novo Nordisk and appears to be more effective than those options. Eli Lilly plans to launch more than six additional Phase 3 trials in 2026 to further test retatrutide across different patient groups.

Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. If results hold, the drug could become a major new player in an already crowded, and highly competitive, weight loss market.